Information Provided By: 
Fly News Breaks for July 11, 2016
MGNX
Jul 11, 2016 | 07:42 EDT
Janney Capital analyst Debjit Chattopadhyay said setbacks in the CAR-T space could renew investor interest in gen-2 bispecific programs, such as MacroGenics' DART's, noting that gen-2 bispecifics are "unburdened by potentially efficacy limiting Flu/Cy-based pre-conditioning regimens" like those that are now a standard across all major CAR-T programs. The analyst has a Buy rating and $36 fair value estimate on MacroGenics shares.
News For MGNX From the Last 2 Days
There are no results for your query MGNX
